Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent

Full Approval Sought After Accelerated Nod Denied Previously

 
• By Mandy Jackson
  
Alzheimer's disease on MRI
Donanemab slowed cognitive decline in Phase III • Source: Shutterstock

More from Clinical Trials

More from R&D